Table 4. Clinical Characteristics of Patients Responsive to Primary Treatment.
| Non-ALCL ALK+ | ALCL ALK+ | |||||
|---|---|---|---|---|---|---|
| With SCT N (%) | Without SCT N (%) | P | With SCT N (%) | Without SCT N (%) | P | |
| All patients | 26 (32) | 56 (68) | 15 (29) | 36 (71) | ||
| Age | ||||||
| Median (range) | 45.3 (19–62) | 63.9 (22–85) | 0.0002 | 31.4 (20–59) | 44.1 (17–79) | 0.0265 |
| ≥60 | 2 (8) | 32 (57) | <0.0001 | 0 (0) | 5 (14) | 0.1286 |
| Sex | ||||||
| Male | 16 (62) | 29 (52) | 0.4089 | 9 (60) | 24 (67) | 0.6499 |
| Histology | ||||||
| PTCL-NOS | 7 (27) | 28 (50) | 0.0209 | 0 | 0 | - |
| ALCL ALK positive | 0 | 0 | 15 (100) | 36 (100) | ||
| ALCL ALK negative | 8 (31) | 15 (27) | 0 | 0 | ||
| AITL | 4 (15) | 11 (20) | 0 | 0 | ||
| EATL | 5 (19) | 1 (1.5) | 0 | 0 | ||
| Others | 2 (8) | 1 (1.5) | 0 | 0 | ||
| Ann Arbor Stage | ||||||
| III–IV | 14 (54) | 39 (70) | 0.1638 | 12 (80) | 16 (44) | 0.0201 |
| IPI | ||||||
| >2 | 6 (23) | 23 (41) | 0.1127 | 6 (40) | 6 (17) | 0.0735 |
| PIT | ||||||
| >2 | 2 (9) | 3 (6) | 0.6185 | 2 (13) | 0 (0) | 0.0519 |
| Relapse/progression | ||||||
| Yes | 9 (35) | 22 (39) | 0.6849 | 2 (13) | 13 (36) | 0.1038 |
| Primary treatment response | ||||||
| CR | 21 (81) | 55 (98) | 0.0048 | 13 (87) | 34 (94) | 0.3465 |
| PR | 5 (19) | 1 (2) | 2 (13) | 2 (6) | ||
| Final response (after autologous SCT) | ||||||
| CR | 25 (96) | - | - | 15 (100) | - | - |
| PR | 1 (4) | - | - | 0 | - | - |
Legend: PTCL-NOS: Peripheral T-Cell Lymphoma Not Otherwise Specified; ALCL: Anaplastic Large-Cell Lymphoma; ALK: Anaplastic Large Cell Lymphoma Kinase; EATL: Enteropathy-Associated T-cell Lymphoma; AITL: Angioimmunoblastic T-cell Lymphoma; Others: includes hepatosplenic T-cell lymphoma (N = 3) and extranodal T/NK-cell lymphoma nasal type (N = 2); SCT: Stem Cell Transplant